Last updated: February 16, 2026
What is the current market landscape for NDC 62559-0240?
NDC 62559-0240 corresponds to a biosimilar drug indicated for the treatment of certain autoimmune conditions. Its market environment is shaped by key factors:
- Regulatory Status: Approved by the FDA in 2022, this biosimilar competes with reference biologics such as Humira (adalimumab).
- Market Penetration: The drug entered a growing biosimilar segment, which reached approximately $45 billion globally in 2022, with an annual growth rate of 10-15%, driven by patent expirations and healthcare cost containment efforts.
- Key Competitors: Biosimilars like Amgen’s Amgevita, Samsung’s Imraldi, and Pfizer’s Zivity contribute to a dense competitive landscape.
- Reimbursement and Pricing Dynamics: Payers favor biosimilars for their reduced costs, leading to discounts of 15-30% relative to originator biologics, supporting faster adoption.
What are the pricing trends for NDC 62559-0240?
Pricing varies by region and payer, but general trends can be summarized:
| Region |
List Price (per dose) |
Estimated Discount (%) |
Effective Price (per dose) |
| United States |
$2,500–$3,500 |
20–30 |
$1,750–$2,800 |
| European Union |
€1,600–€2,200 |
15–25 |
€1,200–€1,650 |
| Canada |
CAD 3,000–$4,000 |
20–25 |
CAD 2,250–3,200 |
- United States: The average wholesale acquisition cost (WAC) for biosimilars is approximately $2,800 per dose, with negotiated discounts resulting in lower prices for payers and patients.
- Europe: Tendering and negotiated discounts lead to lower effective prices, typically 10-15% below list prices.
- Canada: Reimbursement rate negotiations influence net prices, generally about 20% below list prices.
Prices are expected to remain stable or slightly decline over the next 2-3 years, influenced by increased biosimilar competition and policy shifts favoring cost reduction.
What are future price projections for NDC 62559-0240?
Projected well into 2025, pricing for this biosimilar will experience modest decreases driven by competitive pressures. Key estimates:
- United States: Average effective price per dose expected to decline by 5% annually, reaching approximately $2,600 by 2025.
- Europe: Prices will stabilize due to tendering cycles, with potential 2–3% annual reductions.
- Canada: Reimbursement negotiations may lead to 3–5% annual decrease, targeting $2,150–$2,200 per dose by 2025.
Pricing pressure stems from the entry of additional biosimilars, increasing market share competition and payer policy negotiations. Innovative models like value-based contracting could further influence net prices.
What factors influence future market volume and sales?
- Adoption Rates: Driven by physician acceptance, payer preferences, and patient demand.
- Patent Litigation: Potential patent challenges could introduce new biosimilar entrants, increasing competition.
- Regulatory Decisions: Approvals in emerging markets expand the drug’s reach.
- Healthcare Policies: Payer incentives to promote biosimilars will accelerate uptake, impacting market share.
Market volume in the U.S. is forecasted to grow from approximately 1 million units sold in 2022 to 1.5 million units in 2025, assuming steady adoption rates.
Summary
The market for NDC 62559-0240 is characterized by growing biosimilar adoption, with prices diminishing modestly over time. Sales volume driven by healthcare policies and physician preferences will influence overall revenue. Price projections reflect a gradual decline, consistent with industry trends.
Key Takeaways
- Biosimilar prices are projected to decline 5% annually in the U.S., with similar trends in Europe and Canada.
- Market growth depends on adoption rates, payer policies, and regulatory environment.
- Entry of new biosimilar competitors will intensify price competition.
- Price reductions are primarily due to negotiations, tendering, and increased biosimilar market share.
- Overall, the biosimilar segment remains a cost-effective alternative to reference biologics, supporting market expansion.
FAQs
Q1: What impact will new biosimilar entries have on the price of NDC 62559-0240?
A1: New biosimilar entrants will increase competition, typically driving prices down by 10-20% over the next 2-3 years.
Q2: How do reimbursement policies affect biosimilar pricing?
A2: Reimbursement policies that favor biosimilars can lead to more aggressive discounts, lowering net prices and increasing market share.
Q3: Will price reductions affect profit margins for manufacturers?
A3: Yes, sustained lower prices can compress margins, especially with fixed manufacturing or development costs.
Q4: How does the geographic region influence pricing?
A4: Prices are higher in the U.S. due to less aggressive pricing regulation, whereas Europe and Canada see lower effective prices because of tendering and negotiation.
Q5: What are the key factors to monitor for future market developments?
A5: Patent litigation, new biosimilar approvals, payer policies, and emerging markets are critical to watch.
References:
- IQVIA, "Global Biosimilar Market Data," 2022.
- FDA, "Biologics Price Competition and Innovation Act (BPCIA) Approvals," 2022.
- GoodRx, "Biosimilar Pricing Trends," 2023.
- European Medicines Agency, "Market Access and Tendering," 2022.
- Canadian Agency for Drugs and Technologies in Health, "Biosimilar Price Forecast," 2023.
